Imhoff (GTHP) converts notes, exercises warrants and lifts GUIDED THERAPEUTICS common stock holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several stock-accretive transactions. He converted portions of a September 25, 2025 convertible promissory note into 195,460, 312,720 and 156,086 shares of common stock at a conversion price of $0.07 per share, turning principal and accrued interest into equity.
Imhoff also converted 100 shares of Series E preferred stock with a stated value of $1,000 and a $0.25 conversion price into 400,000 common shares, and received additional common shares for accrued Series E dividends. During February 2026, he exchanged 500,000 warrants with a $0.50 exercise price for 500,000 warrants at $0.20, then exercised the new warrants for 500,000 common shares upon payment of $100,000, while extending the expiration of 500,000 warrants at $0.65 by one year. Following the latest reported transactions, he directly holds 21,053,099 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1,164,266 shares exercised/converted
Mixed
15 txns
Insider
Imhoff John E
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Convertible Promissory Note | 156,086 | $0.07 | $11K |
| Other | Preferred Series E Stock | 100 | $0.00 | -- |
| Other | Common Stock | 400,000 | $0.00 | -- |
| Conversion | Common Stock | 156,086 | $0.07 | $11K |
| Other | Warrants | 500,000 | $0.00 | -- |
| Other | Warrants | 500,000 | $0.00 | -- |
| Other | Warrants | 500,000 | $0.00 | -- |
| Other | Warrants | 500,000 | $0.00 | -- |
| X | Warrants | 500,000 | $0.00 | -- |
| X | Common Stock | 500,000 | $0.00 | -- |
| Conversion | Convertible Promissory Note | 312,720 | $0.00 | -- |
| Conversion | Common Stock | 312,720 | $0.07 | $22K |
| Other | Common Stock | 25,338 | $0.00 | -- |
| Conversion | Convertible Promissory Note | 195,460 | $0.00 | -- |
| Conversion | Common Stock | 195,460 | $0.07 | $14K |
Holdings After Transaction:
Convertible Promissory Note — 120,000 shares (Direct);
Preferred Series E Stock — 0 shares (Direct);
Common Stock — 20,897,013 shares (Direct);
Warrants — 0 shares (Direct)
Footnotes (1)
- On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note. These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157. On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note. During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027. On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price. On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
FAQ
What insider transactions did John E. Imhoff report for GUIDED THERAPEUTICS (GTHP)?
John E. Imhoff reported converting multiple portions of a convertible promissory note into common stock, exchanging and exercising warrants, and converting Series E preferred stock into common shares. These actions increased his direct common stock holdings in GUIDED THERAPEUTICS INC.
What were the key note conversion terms reported by John E. Imhoff at GUIDED THERAPEUTICS (GTHP)?
Imhoff converted note balances into common stock at a conversion price of $0.07 per share. Individual conversions covered 195,460, 312,720 and 156,086 shares, turning principal plus accrued interest on a September 25, 2025 convertible promissory note into GUIDED THERAPEUTICS common equity.
What did the warrant exchange and exercise involve for GUIDED THERAPEUTICS (GTHP)?
During February 2026, Imhoff exchanged 500,000 warrants with a $0.50 exercise price for 500,000 warrants at $0.20, then exercised the new warrants for 500,000 common shares upon payment of $100,000. The expiration of 500,000 warrants at $0.65 was extended by one year.
How did John E. Imhoff’s Series E preferred stock affect GUIDED THERAPEUTICS (GTHP) common shares?
Imhoff converted 100 shares of Series E preferred stock, with a stated value of $1,000 and a $0.25 conversion price, into 400,000 common shares. He also received additional common shares issued as payment of accrued dividends on his Series E preferred holdings.
Over what period were these GUIDED THERAPEUTICS (GTHP) insider transactions reported?
The reported transactions span from December 18, 2025 through February 27, 2026. Over this period, Imhoff executed multiple note conversions, a warrant exchange and exercise, a preferred stock conversion, and other restructuring-type entries affecting his GUIDED THERAPEUTICS common stock position.